摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one | 1160107-32-3

中文名称
——
中文别名
——
英文名称
(R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one
英文别名
(3R)-5-but-3-enyl-3-phenyl-2,3-dihydro-1,4-oxazin-6-one
(R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one化学式
CAS
1160107-32-3
化学式
C14H15NO2
mdl
——
分子量
229.279
InChiKey
WYPLEMBFQPRZOZ-ZDUSSCGKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    38.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Spirocycles as Rigidified sp3-Rich Scaffolds for a Fragment Collection
    摘要:
    Novel divergent methodology to access sp3-rich spirocyclic fragments is reported. First, a robust modular synthesis of bis-alkene amino ester building blocks was developed. Three different carbocycles and six heterocycles were then constructed to assemble eight spirocycles. Importantly, strategic exit vectors were incorporated within each scaffold to aid fragment growth and were elaborated via chemical modifications. Finally, computational methods demonstrate higher levels of rigidity, three-dimensionality, and structural diversity of the library compared to a commercial collection.
    DOI:
    10.1021/acs.orglett.9b01499
  • 作为产物:
    描述:
    D-苯甘氨醇2-氧代-5-己酸乙酯2,2,2-三氟乙醇 为溶剂, 反应 0.75h, 以55%的产率得到(R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one
    参考文献:
    名称:
    立体肽的直接立体选择访问。
    摘要:
    描述了由衍生自(R)-苯基甘醇的手性亚氨基内酯制备环状二肽模拟物。合成途径的关键步骤包括完全立体选择性地构建四元中心,通过RCM环化形成六元,七元或八元内酰胺,以及在内酰胺环内引入新的氨基。还报道了三肽模拟物的合成。
    DOI:
    10.1021/jo900679c
点击查看最新优质反应信息

文献信息

  • Straightforward Stereoselective Access to Cyclic Peptidomimetics
    作者:Santos Fustero、Natalia Mateu、Laia Albert、José Luis Aceña
    DOI:10.1021/jo900679c
    日期:2009.6.5
    steps of the synthetic route included the fully stereoselective construction of a quaternary center, the formation of six-, seven-, or eight-membered lactams by means of an RCM cyclization, and the introduction of a new amino group within the lactam ring. The synthesis of a tripeptide mimetic is also reported.
    描述了由衍生自(R)-苯基甘醇的手性亚氨基内酯制备环状二肽模拟物。合成途径的关键步骤包括完全立体选择性地构建四元中心,通过RCM环化形成六元,七元或八元内酰胺,以及在内酰胺环内引入新的氨基。还报道了三肽模拟物的合成。
  • Spirocycles as Rigidified sp<sup>3</sup>-Rich Scaffolds for a Fragment Collection
    作者:Attila Sveiczer、Andrew J. P. North、Natalia Mateu、Sarah L. Kidd、Hannah F. Sore、David R. Spring
    DOI:10.1021/acs.orglett.9b01499
    日期:2019.6.21
    Novel divergent methodology to access sp3-rich spirocyclic fragments is reported. First, a robust modular synthesis of bis-alkene amino ester building blocks was developed. Three different carbocycles and six heterocycles were then constructed to assemble eight spirocycles. Importantly, strategic exit vectors were incorporated within each scaffold to aid fragment growth and were elaborated via chemical modifications. Finally, computational methods demonstrate higher levels of rigidity, three-dimensionality, and structural diversity of the library compared to a commercial collection.
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 6-amino-4-phenyl-4H-1,2-oxazine-3,5-dicarbonitrile (2S,5R)-2-hydroxy-5,6-dihydro-2-ethyl-3-methyl-5-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-3-methyl-2,5-diphenyl-2H-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3,5-trimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-6-phenyl-2-propyl-2H-1,4-oxazine (Z)-methyl-2-((R)-5-(2-(methylthio)ethyl)-3-oxomorpholin-2-ylidene)acetate (Z)-methyl-2-((R)-5-benzyl-3-oxomorpholin-2-ylidene)acetate (2R,5R,6S)-5,6-dihydro-3,6-diphenyl-2-hydroxy-5-methyl-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine 2-heptafluoropropyl-3-trifluoromethyl-5,6-dihydro-1,4-oxazin-2-ol (2S,5R,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine 6H-1,2-Oxazine 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine 3-(chloromethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 3-(acetoxymethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 6-Butyl-2,4-diphenyl-4H-[1,3]oxazine 2-methyl-2,4,6-triphenyl-2H-1,3-oxazine (S)-2,4,6-triphenyl-4H-1,3-oxazine 2-Isopropenyl-6-phenyl-6-piperidin-1-yl-6H-[1,3]oxazin-4-ol 5-methyl-6-perhydroxy-3-phenyl-6H-1,2-oxazine 5-methyl-3-phenyl-6-(prop-2-yn-1-oxy)-6H-1,2-oxazine 2,2,3,3,6,6-Hexafluoro-5-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-3,6-dihydro-2H-[1,4]oxazine 4,4-Dimethyl-2-phenyl-1,3-oxazine (R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one Acetic acid 3,5-dimethyl-6-oxo-3,6-dihydro-2H-[1,4]oxazin-3-ylmethyl ester (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol